Get the Stockscreener App
12.58
1.37%
0.17
After Hours:
12.58
Phathom Pharmaceuticals Inc stock is traded at $12.58, with a volume of 950.45K.
It is up +1.37% in the last 24 hours and down -23.15% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$12.41
Open:
$12.82
24h Volume:
950.45K
Relative Volume:
0.92
Market Cap:
$981.41M
Revenue:
$114.04M
Net Income/Loss:
$-330.15M
P/E Ratio:
-2.6596
EPS:
-4.73
Net Cash Flow:
$-274.85M
1W Performance:
-7.97%
1M Performance:
-23.15%
6M Performance:
+44.93%
1Y Performance:
+113.22%
1-Day Range:
$12.20
$12.94
1-Week Range:
$12.20
$14.53
52-Week Range:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.58 | 968.15M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Raymond James | Strong Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewswire
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment - Traders Union
(PHAT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stop Loss: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Analysis Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Stock Market Recap: What is Phathom Pharmaceuticals Incs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Intraday Trade Alerts - baoquankhu1.vn
Momentum Shift: Can NTST maintain its current growth ratePortfolio Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Aug Final Week: What is Phathom Pharmaceuticals Incs book value per share2025 Technical Overview & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Millennium Management LLC Reduces Stake in Phathom Pharmaceuticals Inc - GuruFocus
What are the risks of holding Phathom Pharmaceuticals Inc.2025 Dividend Review & Advanced Technical Analysis Signals - mfd.ru
Is Phathom Pharmaceuticals Inc. a cyclical or defensive stockPortfolio Performance Summary & Growth Focused Entry Reports - mfd.ru
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AIGH Capital Management LLC Acquires Shares of 429,000 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Aug Drivers: Is DENNs growth already priced inJuly 2025 Trade Ideas & Precise Buy Zone Tips - baoquankhu1.vn
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - 富途资讯
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Investment Review: Is Alexanders Inc a momentum stockJuly 2025 Volume & Technical Pattern Based Signals - baoquankhu1.vn
Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook - Investing.com Canada
Breakeven On The Horizon For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - 富途牛牛
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 By Investing.com - Investing.com Canada
Bond Watch: Whats Phathom Pharmaceuticals Incs historical return2025 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
(PHAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Phathom Pharmaceuticals: VOQUEZNA hits 1 million U.S. prescriptions milestone - Traders Union
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6%Here's What Happened - MarketBeat
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Should Phathom’s US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? - Yahoo Finance
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - Улправда
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - marketscreener.com
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - Улправда
What's Going On With Phathom Pharma Stock Thursday?Phathom Pharmaceuticals (NASDAQ:PHAT) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals prices $130 million public offering - Investing.com
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):